Anti-obesity drug also protects against heart disease — what happens next?

Mariana Lenharo

Nature, 2023, vol. 620, issue 7974, 480-480

Abstract: Clinical-trial data suggest that semaglutide, sold under the name Wegovy, slashes risk of heart attacks and other cardiovascular incidents.

Keywords: Obesity; Cardiovascular biology; Medical research; Metabolism (search for similar items in EconPapers)
Date: 2023
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/d41586-023-02528-2 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:620:y:2023:i:7974:d:10.1038_d41586-023-02528-2

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/d41586-023-02528-2

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().